TY - JOUR
AU1 - Puza, Charles J.
AU2 - Pyle, Hunter J.
AU3 - Srivastava, Divya
AU4 - Nijhawan, Rajiv I.
AB - Archives of Dermatological Research https://doi.org/10.1007/s00403-023-02701-7 SHOR T REPOR T Immune checkpoint inhibitors and dermatologic procedures: a retrospective review of postoperative complications 1 1 1 1 Charles J. Puza  · Hunter J. Pyle  · Divya Srivastava  · Rajiv I. Nijhawan Received: 18 March 2023 / Revised: 30 May 2023 / Accepted: 2 August 2023 © The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2023 In 2011, with ipilimumab, immune checkpoint inhibitors (8/48, 16.7%), and MMS (23/48, 47.9%). ICI indications (ICI) gained FDA approval for the treatment of metastatic included malignant melanoma (20/25, 80.0%), lung adeno- melanoma [4]. Since then, indications have been broadened carcinoma (2/25, 8.0%), bladder carcinoma (1/25, 4.0%), to include malignancies such as squamous cell carcinoma, renal cell carcinoma (1/25, 4.0%), and cholangiocarcinoma Merkel cell carcinoma, lung cancer, hepatocellular car- (1/25, 4.0%). Procedural locations included head and neck cinoma, renal cell carcinoma, and urogenital carcinoma. (22/48, 45.8%), extremities (17/48, 35.4%), and trunk (9/48, As indications for ICI expand, more patients on ICI will 18.8%). ICI therapy included nivolumab (16/25, 64.0%), undergo dermatologic procedures. The adverse effects of pembrolizumab (5/25, 20.0%), ipilimumab (1/25, 4.0%), and ICI therapy are largely secondary to immune system activa- combination nivolumab and ipilimumab (3/25, 12.0%). Post- tion, including colitis, 
TI - Immune checkpoint inhibitors and dermatologic procedures: a retrospective review of postoperative complications
JF - Archives of Dermatological Research
DO - 10.1007/s00403-023-02701-7
DA - 2023-12-01
UR - https://www.deepdyve.com/lp/springer-journals/immune-checkpoint-inhibitors-and-dermatologic-procedures-a-SaxsO1sFy8
SP - 2941
EP - 2942
VL - 315
IS - 10
DP - DeepDyve
ER -